Search

Your search keyword '"Pol, Stanislas"' showing total 1,987 results

Search Constraints

Start Over You searched for: Author "Pol, Stanislas" Remove constraint Author: "Pol, Stanislas"
1,987 results on '"Pol, Stanislas"'

Search Results

1. Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort

4. Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort

5. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes

6. Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide

8. Unknown Circovirus in Immunosuppressed Patient with Hepatitis, France, 2022

10. Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors

11. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?

13. Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis

14. Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort

15. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D

16. WED-245 Should specific cutoffs be used for diagnosing fibrotic MASH in patients with type 2 diabetes using FAST, MAST, MEFIB and FNI?

17. GS-002 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204

19. FRI-371 Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy

20. WED-410 Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort

21. WED-391 Long-term virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with bulevirtide monotherapy for up to 120 weeks: a retrospective multicenter european study (save-d)

22. OS-120 Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis

24. OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: the prospective multicentric PET HCC01 study

25. OS-060 Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR)

26. Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

28. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

29. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

30. Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort

32. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

33. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes

36. Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance

37. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

38. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area

40. The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during the surveillance of patients with cirrhosis.

41. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

42. Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline

43. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies

49. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy

Catalog

Books, media, physical & digital resources